176 related articles for article (PubMed ID: 34980443)
21. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
22. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
23. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.
Kahsay A; Rodriguez-Marquez E; López-Pérez A; Hörnblad A; von Hofsten J
Sci Rep; 2022 Oct; 12(1):17149. PubMed ID: 36229514
[TBL] [Abstract][Full Text] [Related]
24. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
25. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
[TBL] [Abstract][Full Text] [Related]
26. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine Induces Apoptosis and Down-regulation of
Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K
Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
29. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.
Rengaswamy V; Zimmer D; Süss R; Rössler J
J Control Release; 2016 Aug; 235():319-327. PubMed ID: 27261335
[TBL] [Abstract][Full Text] [Related]
30. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract][Full Text] [Related]
31. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
Parham DM; Qualman SJ; Teot L; Barr FG; Morotti R; Sorensen PH; Triche TJ; Meyer WH;
Am J Surg Pathol; 2007 Jun; 31(6):895-901. PubMed ID: 17527077
[TBL] [Abstract][Full Text] [Related]
32. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH; Mercado GE; Laé M; Ladanyi M
Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
[TBL] [Abstract][Full Text] [Related]
33. Classification of rhabdomyosarcoma and its molecular basis.
Parham DM; Barr FG
Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
[TBL] [Abstract][Full Text] [Related]
34. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.
Kelly KM; Womer RB; Sorensen PH; Xiong QB; Barr FG
J Clin Oncol; 1997 May; 15(5):1831-6. PubMed ID: 9164192
[TBL] [Abstract][Full Text] [Related]
35. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
[TBL] [Abstract][Full Text] [Related]
36. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
37. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.
Liu J; Guzman MA; Pezanowski D; Patel D; Hauptman J; Keisling M; Hou SJ; Papenhausen PR; Pascasio JM; Punnett HH; Halligan GE; de Chadarévian JP
Mod Pathol; 2011 Oct; 24(10):1327-35. PubMed ID: 21666686
[TBL] [Abstract][Full Text] [Related]
38. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
39. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition.
Gonzalez Curto G; Der Vartanian A; Frarma YE; Manceau L; Baldi L; Prisco S; Elarouci N; Causeret F; Korenkov D; Rigolet M; Aurade F; De Reynies A; Contremoulins V; Relaix F; Faklaris O; Briscoe J; Gilardi-Hebenstreit P; Ribes V
PLoS Genet; 2020 Nov; 16(11):e1009164. PubMed ID: 33175861
[TBL] [Abstract][Full Text] [Related]
40. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
Barr FG; Smith LM; Lynch JC; Strzelecki D; Parham DM; Qualman SJ; Breitfeld PP
J Mol Diagn; 2006 May; 8(2):202-8. PubMed ID: 16645206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
